拓新药业
(301089)
| 流通市值：30.72亿 | | | 总市值：49.29亿 |
| 流通股本：7888.24万 | | | 总股本：1.27亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 292,747,146.46 | 148,553,750.34 | 296,836,454.7 | 105,139,373.76 |
| 应收票据及应收账款 | 122,330,574.36 | 203,339,038.92 | 226,361,763.92 | 227,573,129.17 |
| 其中：应收票据 | 18,356,752.87 | 51,661,058.82 | 28,849,299.41 | 14,832,110 |
| 应收账款 | 103,973,821.49 | 151,677,980.1 | 197,512,464.51 | 212,741,019.17 |
| 应收款项融资 | 62,385,289.55 | 31,957,118.51 | 48,195,095.99 | 44,314,318.6 |
| 预付款项 | 10,537,661.19 | 4,262,516.92 | 12,279,059.96 | 10,547,003.08 |
| 其他应收款合计 | 150,610.62 | 46,960.81 | 148,525.59 | 74,089.8 |
| 存货 | 187,947,995.73 | 204,110,789.91 | 256,247,113.92 | 250,434,999.54 |
| 其他流动资产 | 39,329,805.61 | 39,194,604.83 | 21,093,797.78 | 19,622,251.07 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 785,429,083.52 | 822,169,778.54 | 916,161,811.86 | 983,832,454.69 |
| 非流动资产: | | | | |
| 长期股权投资 | 1,450,893.45 | 1,450,893.45 | 1,451,008.96 | 1,451,008.96 |
| 其他权益工具投资 | 6,921,006.21 | 6,921,006.21 | 9,413,468.8 | 9,413,468.8 |
| 固定资产 | 470,245,886.92 | 478,348,414.04 | 462,042,664.85 | 467,069,517.89 |
| 在建工程 | 359,986,115.94 | 331,031,336.05 | 217,539,810.48 | 207,715,682.2 |
| 无形资产 | 83,123,568.39 | 84,041,925.97 | 82,913,747.21 | 83,589,975.44 |
| 长期待摊费用 | 2,433,353.24 | 2,702,907.82 | 2,005,111.34 | 1,620,454.04 |
| 递延所得税资产 | 63,147,981.86 | 63,705,501.66 | 83,922,426.7 | 69,700,799.74 |
| 其他非流动资产 | 46,130,569.7 | 48,622,798.24 | 86,281,274.37 | 65,214,632.17 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,033,439,375.71 | 1,016,824,783.44 | 945,569,512.71 | 905,775,539.24 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,818,868,459.23 | 1,838,994,561.98 | 1,861,731,324.57 | 1,889,607,993.93 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 148,006,399.11 | 152,548,234.96 | 105,015,654.88 | 131,792,622.41 |
| 其中：应付票据 | 40,783,626.98 | 42,159,549.27 | 44,823,182.49 | 48,032,482.36 |
| 应付账款 | 107,222,772.13 | 110,388,685.69 | 60,192,472.39 | 83,760,140.05 |
| 合同负债 | 956,586.92 | 5,482,986.93 | 871,036.63 | 2,246,066.78 |
| 应付职工薪酬 | 8,108,042.26 | 18,304,515.79 | 7,545,509.35 | 7,947,677.08 |
| 应交税费 | 3,207,853.98 | 2,821,805.47 | 6,113,441.08 | 35,383,447.48 |
| 其他应付款合计 | 1,529,626.94 | 3,646,301.48 | 3,762,816.26 | 3,669,944.17 |
| 其他流动负债 | 10,479,376.57 | 11,708,395.75 | 26,045,897.97 | 9,680,912.78 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 172,287,885.78 | 194,512,240.38 | 149,354,356.17 | 190,720,670.7 |
| 非流动负债: | | | | |
| 递延收益 | 35,379,295.19 | 35,173,175.6 | 35,956,955 | 36,740,734.4 |
| 递延所得税负债 | 5,861,027.83 | 6,037,277.4 | 4,577,887.38 | 4,856,219.4 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 41,240,323.02 | 41,210,453 | 40,534,842.38 | 41,596,953.8 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 213,528,208.8 | 235,722,693.38 | 189,889,198.55 | 232,317,624.5 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 126,544,500 | 126,544,500 | 126,000,000 | 126,000,000 |
| 资本公积 | 621,109,964.85 | 621,109,964.85 | 617,980,266.19 | 607,086,399 |
| 其他综合收益 | 1,440,754.65 | 1,440,754.65 | 3,567,111.59 | 3,567,111.59 |
| 盈余公积 | 65,222,535.36 | 65,222,535.36 | 55,936,478.09 | 55,936,478.09 |
| 未分配利润 | 791,022,495.57 | 788,954,113.74 | 868,358,270.15 | 864,700,380.75 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,605,340,250.43 | 1,603,271,868.6 | 1,671,842,126.02 | 1,657,290,369.43 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,605,340,250.43 | 1,603,271,868.6 | 1,671,842,126.02 | 1,657,290,369.43 |
| 负债和股东权益合计 | 1,818,868,459.23 | 1,838,994,561.98 | 1,861,731,324.57 | 1,889,607,993.93 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-25 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |